US4906475A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Estradiol transdermal delivery system
Assignee: Paco Pharmaceutical Services Inc
•
Filing: 1988-02-16
•
Granted: 1990-03-06
•
Expires: 2008-02-16
Abstract
Abstract The present invention is directed to a transdermal delivery system for an active substance. The active substance is estrogen or its derivatives and preferably is 17-beta-estradiol. The system comprises an impermeable backing layer and a matrix affixed thereto. The matrix comprises, on a weight percentage basis, from about 60 to about 95% of an adhesive polymer, from about 5 to about 20% of a solvent, from about 0.2 to about 4% of a skin penetration enhancer, and from about 0.5 to about 5% of the active substance. The system is free of any discrete permeable, polymeric, diffusion-controlling membrane.
Inventors
- 👤 Benjamin K. Kim
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 17:38
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K9/7061; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
91 words
A transdermal delivery system comprises: an impermeable backing layer; a matrix affixed to said backing layer and comprising on a weight percentage basis from about 60 to about 95% of an adhesive vinyl acetate-acrylate multipolymer, from about 5 to about 20% of a solvent, from about 0.2 to about 4% of a skin penetration enhancer, and from about 0.5 to about 5% of an active substance selected from the group consisting of estrogen, derivatives of estrogen and combinations thereof; and said system being free of any discrete, permeable, polymeric, diffusion-controlling membrane.
Claim 2
Dependent Claim
91 words
A transdermal delivery system comprises: an impermeable backing layer; a matrix affixed to said backing layer and comprising on a weight percentage basis from about 60 to about 95% of an adhesive vinyl acetate-acrylate multipolymer, from about 5 to about 20% of a solvent, from about 0.2 to about 4% of a skin penetration enhancer, and from about 0.5 to about 5% of an active substance selected from the group consisting of estrogen, derivatives of estrogen and combinations thereof; and said system being free of any discrete, permeable, polymeric, diffusion-controlling membrane.
Claim 3
Dependent Claim
12 words
The system according to claim 1 wherein said active substance is 17-beta-estradiol.
Claim 4
Dependent Claim
24 words
The system according to claim 1 wherein said solvent is selected from the group consisting of propylene glycol, propylene glycol derivatives and combinations thereof.
Claim 5
Dependent Claim
45 words
The system according to claim 1 wherein said solvent is selected from the group consisting of polyethylene glycol having approximate molecular weights of 200, 300, 400, 500, 600 and 800, and polyethylene glycol ester such as polyethylene glycol monolaurate, mono-oleate, and monolaurate, and combinations thereof.
Claim 6
Dependent Claim
15 words
The system according to claim 1 wherein said skin penetration enhancer is a polyoxyethylene ester.
Claim 7
Dependent Claim
18 words
The system according to claim 1 wherein said skin penetration enhancer is sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) and its derivatives.
Claim 8
Dependent Claim
27 words
The system according to claim 1 further comprising a release layer, whereby said matrix is sandwiched between said backing layer and said release layer prior to use.
Claim 9
Dependent Claim
107 words
A transdermal delivery system comprises: an impermeable backing layer; a matrix affixed to said backing layer and comprising on a weight percentage basis from about 60 to about 95% of an adhesive vinyl acetate-acrylate multipolymer, from about 5 to about 20% of a solvent selected from the group consisting of propylene glycol, propylene glycol derivatives and combinations thereof, from about 0.2 to about 4% of a polyoxyethylene ester skin penetration enhancer, and from about 0.5 to about 5% of an active substance selected from the group consisting of estrogen, derivatives of estrogen and combinations thereof; and said system being free of any discrete, permeable, polymeric, diffusion-controlling membrane.
Claim 10
Dependent Claim
107 words
A transdermal delivery system comprises: an impermeable backing layer; a matrix affixed to said backing layer and comprising on a weight percentage basis from about 60 to about 95% of an adhesive vinyl acetate-acrylate multipolymer, from about 5 to about 20% of a solvent selected from the group consisting of propylene glycol, propylene glycol derivatives and combinations thereof, from about 0.2 to about 4% of a polyoxyethylene ester skin penetration enhancer, and from about 0.5 to about 5% of an active substance selected from the group consisting of estrogen, derivatives of estrogen and combinations thereof; and said system being free of any discrete, permeable, polymeric, diffusion-controlling membrane.
References Cited (Backward Citations)
US3767786A
Cited
GB1001949A
Cited
US3249109A
Cited
US3426754A
Cited
GB1108837A
Cited
US3527864A
Cited
US3464413A
Cited
US3632740A
Cited
US3472931A
Cited
US3993073A
Cited
US3598123A
Cited
US3598122B1
Cited
US3598122A
Cited
US3797494A
Cited
US3699963A
Cited
US3641237A
Cited
US4069307A
Cited
US3737521A
Cited
US3867520A
Cited
US3964482A
Cited
US3731683A
Cited
US3996934A
Cited
US3742951A
Cited
US3742951B1
Cited
US3892842A
Cited
US3948254A
Cited
US3903256A
Cited
US3896238A
Cited
US3849238A
Cited
US3783869A
Cited
US3903880A
Cited
US4016251A
Cited
US3921636A
Cited
US3952099A
Cited
FR2224140B1
Cited
FR2224126B1
Cited
US4177256A
Cited
US3993072A
Cited
US4012497A
Cited
US3992518A
Cited
US3946106A
Cited
US3926188A
Cited
US3969516A
Cited
US3932653A
Cited
US4053580A
Cited
US4046886A
Cited
US4180646A
Cited
US4039664A
Cited
US3972995A
Cited
US4096239A
Cited
US4144317A
Cited
US4405616A
Cited
US4077407A
Cited
US4436741A
Cited
US4031894A
Cited
US4262003A
Cited
US4018889A
Cited
US4130643A
Cited
US4130667A
Cited
US4058122A
Cited
US4060084A
Cited
US4335115A
Cited
US4127127A
Cited
US4201211A
Cited
US4675009A
Cited
US4162243A
Cited
GB2021950B
Cited
FR2437830B1
Cited
US4230105A
Cited
US4291014A
Cited
US4579731A
Cited
US4237888A
Cited
US4409206A
Cited
US4321252A
Cited
US4292303A
Cited
US4470962A
Cited
US4466953A
Cited
US4438139A
Cited
US4289749A
Cited
US4294820A
Cited
US4292301A
Cited
US4291015A
Cited
US4492685A
Cited
US4292302A
Cited
US4299826A
Cited
US4286592A
Cited
US4314557A
Cited
US4297995A
Cited
US4558580A
Cited
US4336243A
Cited
US4552751A
Cited
US4505891A
Cited
US4390520A
Cited
US4533540A
Cited
US4482534A
Cited
US4420470A
Cited
US4460372A
Cited
US4379454A
Cited
US4485087A
Cited
US4591501A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-05 | 1993-09-04 | 1994-03-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-05 | 1997-09-04 | 1998-03-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-05 | 2001-09-04 | 2002-03-06 | $7700.00 | Window Closed / Lapsed |